IL2 and type 1 diabetes mellitus: Treatment with low-dose IL-2 has shown promise in numerous inflammatory disorders including chronic graft vs.-host-disease (GVHD), allograft survival, systemic lupus erythematosus, and type I diabetes, among others (20, 21).